Children and young adults treated with transvenous and subcutaneous implantable cardioverter-defibrillators: a 22-year single-center experience and new perspectives.

CONCLUSIONS: The mortality rate was 6/80 (7.5%), in the twenty-two-year follow-up. The rate of AT vs. IT was almost equal and remained steady in the long observation period. Severe TR might be a serious clinical problem in some patients. Entirely subcutaneous system (S-ICD) for SCD prevention is a feasible and safe therapy in young recipients. PMID: 32631024 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32631024?dopt=Abstract

Source: Kardiologia Polska - July 1, 2020 Category: Cardiology Authors: Lewandowski M, Syska P, Kowalik I Tags: Kardiol Pol Source Type: research